Reishi Mushroom Benefits: Evidence and Safety Review

Bottom line

“Reishi” can refer to different Ganoderma species and many preparations: fruiting-body powder, spores, mycelium, hot-water extract, alcohol extract, or combinations. These materials are not interchangeable. Traditional use and laboratory activity do not establish clinical effectiveness.

The Cochrane review of Ganoderma lucidum in cancer care found a small group of trials with methodological limitations. It did not support using Ganoderma as first-line cancer treatment, and the included studies did not establish long-term survival. Some intermediate immune measurements or short-term response outcomes cannot substitute for survival, disease progression, quality of life, and well-characterized harms.

Reading newer pooled results carefully

Later meta-analyses combine trials across populations, products, doses, and outcomes. Pooling can produce a numerical estimate, but it cannot repair weak randomization, incomplete blinding, selective reporting, short follow-up, or uncertain product authentication. A statistically detectable change in BMI, heart rate, a laboratory marker, or an immune-cell measure is not automatically clinically important and does not prove a broad “reishi benefit.”

The most defensible conclusion is that particular standardized preparations remain research subjects. Evidence for one trial product cannot be applied to a tea, whole mushroom, spore oil, or retail capsule without demonstrating equivalence.

Product identity and claim checking

Record the accepted scientific name, fungal part, extraction method, dose per serving, measured marker compounds, independent identity testing, contaminant testing, manufacturer, and lot number. Be cautious when a seller cites only cell studies, animal studies, or a trial that used a different product. “Clinically studied ingredients” is not the same as testing the product in the bottle.

Safety

Concentrated fungal products can cause adverse effects and may interact with treatment. Evidence for pregnancy, breastfeeding, children, perioperative use, and many chronic conditions is limited. Cancer patients should not add reishi without discussing it with the oncology team; interactions, liver injury concerns, bleeding risk, and changes to treatment adherence require individualized assessment.

Market availability is not FDA preapproval for effectiveness. Never replace chemotherapy, immunotherapy, radiation, surgery, or another prescribed therapy with reishi. See the reishi species guide for taxonomy and the supplement label guide for product checks.

References

1. Cochrane review: Ganoderma for cancer treatment
2. GRADE-assessed systematic review and meta-analysis
3. FDA 101: Dietary Supplements